Progyny, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023. The unaudited filing was signed November 8, 2023. Progyny provides employer fertility benefits and an integrated pharmacy benefits solution, operating as one segment.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $280.9 million | $205.4 million | $818.7 million | $572.6 million |
| Gross profit / margin | $62.6 million / 22.3% | $46.0 million / 22.4% | $181.9 million / 22.2% | $122.8 million / 21.5% |
| Operating income / margin | $18.2 million / 6.5% | $11.3 million / 5.5% | $48.4 million / 5.9% | $20.0 million / 3.5% |
| Net income | $15.9 million | $13.2 million | $48.6 million | $27.0 million |
| Diluted EPS | $0.16 | $0.13 | $0.48 | $0.27 |
| Adjusted EBITDA | $50.0 million | $35.0 million | $143.8 million | $92.6 million |
- Q3 revenue rose 37% year over year; nine-month revenue rose 43%. Fertility benefits revenue increased 35% in Q3 and 38% year to date; pharmacy benefits revenue increased 39% and 53%, respectively.
- Gross margin was nearly flat in Q3, down 10 basis points, while year-to-date margin improved 70 basis points. Management cited care-management efficiencies, partly offset by personnel costs and cost-containment savings shared with clients.
- Q3 net income margin was 5.7%, versus 6.4%; nine-month net income margin was 5.9%, versus 4.7%. The 2023 periods included income tax expense, compared with tax benefits in 2022.
- Stock-based compensation was $31.3 million in Q3 and $93.8 million for nine months, compared with $23.3 million and $71.5 million, respectively, in 2022.
Cash, liquidity and balance sheet
- At September 30, 2023, cash and cash equivalents were $158.1 million and marketable securities were $177.5 million, together $335.6 million. Current assets were $611.3 million and current liabilities were $193.4 million.
- Net cash from operating activities was $151.2 million for the nine months, compared with $28.9 million in 2022. The increase reflected earnings and noncash items, as well as timing and improved payment terms with pharmacy partners; accounts receivable growth used $43.8 million of cash.
- Investing activities used $107.1 million, primarily net purchases of marketable securities; financing activities used $6.0 million, primarily employee tax withholding on equity awards.
- The balance sheet reports no borrowings or debt. Lease liabilities totaled $19.5 million, including $1.8 million current and $17.7 million noncurrent. Total liabilities were $211.1 million and stockholders’ equity was $515.4 million.
- Management believes cash, marketable securities and operating cash flow will fund working capital and capital needs for at least the next 12 months.
Business changes and management commentary
- Clients increased to 392 from 288 at December 31, 2022; covered lives rose to approximately 5.46 million from 4.59 million. About 90% of current clients had launched Progyny Rx.
- Q3 assisted reproductive treatment cycles increased to 15,005 from 11,086; nine-month cycles increased to 42,947 from 30,402. All-member utilization was 0.56% in Q3 versus 0.49%, and 1.11% year to date versus 1.00%.
- One client represented 13% of revenue for the first nine months of 2023. Two clients represented a combined 26% in the comparable 2022 period. Management also notes meaningful exposure to technology-industry clients.
- Accounts receivable, net, was $268.8 million, including an allowance for doubtful accounts of $42.9 million, up from $28.3 million at year-end 2022. Bad debt expense was $15.1 million for the nine months.
- Management said COVID-19 negatively affected revenue growth in the 2022 comparison period. It expects moderate seasonality, with a greater share of revenue generally in the second half of the year.
- Management reported effective disclosure controls as of September 30, 2023, with no material changes in internal control over financial reporting during the quarter.
Outlook, risks and contingencies
- The filing says Progyny issued Q4 and full-year 2023 guidance on November 7, 2023, but the supplied filing text does not provide a clear numerical guidance value.
- Key risks include retaining and expanding clients, competition, utilization and treatment mix, client concentration, economic weakness, provider-network stability, and specialty-pharmacy pricing or medication supply disruptions.
- The company operates in a complex and changing regulatory environment, including rules affecting healthcare benefits, pharmacy benefit managers, privacy and data security, and reproductive healthcare. State restrictions may affect fertility services or related benefits.
- Cybersecurity incidents, data privacy failures, and disruptions at clinics, pharmacies or other vendors could impair services, trigger liability or harm the company’s reputation. The company reports past attempted cyberattacks but says none had a material adverse impact.
- Management disclosed no known legal proceedings or claims expected to have a material adverse effect. The filing also describes future facility lease commitments and states there were no defaults upon senior securities.
Important facts for investors to verify
- Review the November 7, 2023 earnings release or call for the numerical Q4 and full-year guidance and its assumptions.
- Assess whether client and covered-life growth, utilization and pharmacy adoption can continue, and monitor renewal, pricing and expansion trends.
- Track gross-margin movement, treatment and drug costs, cost-containment arrangements, and the rising level of stock-based compensation.
- Monitor receivable aging, bad-debt allowances, collections and pharmacy-partner payment terms, given the high receivables balance and operating cash-flow sensitivity to timing.
- Evaluate exposure to the largest client and technology-sector clients, as well as regulatory, reproductive-health, cybersecurity and medication-supply developments.